Ronald L Krall

Learn More
Thirty-two patients with spasticity due to multiple sclerosis were entered into a randomized, double-blinded, placebo-controlled crossover trial of the gamma-aminobutyric acid agonist, progabide. Each patient was treated with a maximum of 45 mg/kg of progabide during each of two four-week treatment periods, separated by a two-week washout. Twenty-five(More)
We agree with the thesis of Rosen et al. [1] that, despite initiatives such as the World Health Organization's " 3 by 5 " program, rationing of HIV/AIDS antiretroviral therapy (ART) will be necessary in the majority of African countries. Diffi cult choices will need to be made, and choices will be constrained due to the limited health infrastructure and(More)
A critical challenge facing the advocates of biotechnology is to fortify the biosafety of genetically engineered organisms. Readers of this journal have seen competing notions on how to achieve biosafety. For some, scientists carry the burden of designing better biosafety through 'backup safety precau-tions' 1 and 'molecular gene-containment strategies' 2.(More)
Twenty-one episodes of status epilepticus (SE) were each treated with 1 to 9 mg (mean, 4 mg) of intravenous lorazepam. All patients with generalized tonic-clonic ( GTC ) SE responded within 15 minutes. Nine (82%) of the 11 patients with episodes of partial SE with altered responsiveness responded poorly. Respiratory depression occurred in five instances(More)
  • 1